Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Smiths Group sees FY revenue growth towards top end of guidance

(Sharecast News) - Smiths Group said on Tuesday that it now expects full-year revenue growth to be towards the top end of its guidance amid strong demand. The company said third-quarter organic revenue growth accelerated to 10.6%, leading to organic revenue growth of 9.6% for the nine-month period.

As a result, "reflecting this strong performance and momentum in the order book", it now expects organic revenue growth for the year to be towards the top end of its 6-8% guidance range and continues to expect margin expansion of 40-60 basis points for FY2025.

Smiths said the third-quarter performance reflected further growth across all businesses, with particularly strong organic revenue growth in Smiths Detection and Smiths Interconnect - a continuation of the trends seen in the first half.

At John Crane and Flex-Tex, momentum improved from the second quarter.

The diversified engineer, which generates around 45% of its sales in the US, also said that it expects the impact of tariffs to be limited given its local-for-local model, and through the deployment of mitigation actions.

Chief executive Roland Carter said: "Our strong performance has continued through the third quarter and all our businesses contributed to the double-digit organic revenue growth.

"This consistency of delivery has now underpinned successive earnings upgrades this year and multiple years of organic revenue growth for Smiths.

"We are executing on the strategic actions we announced in January with pace and purpose to unlock our inherent value and become a premium rated company, focusing on our world-class, high-performance John Crane and Flex-Tek businesses. The sale process for Smiths Interconnect is firmly underway and preparatory work for the Smiths Detection separation process is also moving forwards."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.